Aspirin in the XXI century: Its major clinical impact, novel mechanisms of action, and new safer formulations

Gastroenterology

Volumn 127, Issue 1, 2004, Pages 341-343

  Tarnawski, Andrzej S ^a   Caves, Thomas C ^a  

^a VA LONG BEACH HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANALGESIC AGENT; ANTIRHEUMATIC AGENT; CARDIAC AGENT; IBUPROFEN; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT;

ARTHRITIS; CARDIOVASCULAR DISEASE; CHRONIC PAIN; CLINICAL TRIAL; DIGESTIVE SYSTEM INJURY; DRUG ABSORPTION; DRUG COST; DRUG DOSAGE FORM; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG INDICATION; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; DRUG SYNTHESIS; EDITORIAL; ENZYME INHIBITION; GASTROINTESTINAL SYMPTOM; HEART PROTECTION; HUMAN; PAIN; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; THROMBOCYTE AGGREGATION INHIBITION;

EID: 3242657470     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2004.05.037     Document Type: Editorial

References (29)

1. ISIS-2 (Secondary International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction ISIS-2. Lancet. 13:1988;349-360
2. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high-risk patients. BMJ. 324:2002;71-86
3. Hung J. Medical Issues Committee of the National Heart Foundation of Australia. Aspirin for cardiovascular disease prevention. Med J Aust. 179:2003;147-152
4. Vane J.R. Inhibition of prostaglandin synthesis as a mechanism of action of aspirin-like drugs. Nature. 231:1971;232-251
5. Vane J. The mechanisms of action of aspirin like drugs in aspirin - medicine of the century. 1997;. Proceeding of the Centennial Anniversary of Aspirin Symposium, April 20-24, Venice, Italy
6. DuBois R.N., Abramson S.B., Crofford L., Gupta R.A., Simon L.S., Van De Putte L.B.A., Lipsky P.E. Cyclooxygenase in biology and disease. FASEB J. 12:1998;1963-1973
7. Warner T.D., Mitchell J.A. Cyclooxygenases new forms, new inhibitors, and lessons from the clinic. FASEB J. 18:2004;790-804
8. Halter F., Tarnawski A.S., Schmassmann A., Peskar B.M. Cyclooxygenase 2 - implications on maintenance of gastric mucosal integrity and ulcer healing controversial issues and perspectives. Gut. 49:2001;443-453
9. Ebberhart C.E., Coffey R.J., Radhika A., Giardiello F.M., Ferrenbach S., DuBois R.N. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology. 197:1994;1183-1188
10. Bombardier C., Laine L., Reicin A., Shapiro D., Burgos-Vargas R., Davis B., Day R., Ferraz M.B., Hawkey C.J., Hochberg M.C., Kvien T.K., Schnitzer T.J. VIGOR Study Group. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med. 343:2000;1520-1528
11. Sibilia J., Ravaud P., Marck G. Digestive and hemorrhage complications of low-dose aspirin. Presse Med. 32:(Suppl):2003;S9-S16
12. Derry S., Loke Y.K. Risk of gastrointestinal hemorrhage with long-term use of aspirin meta-analysis. BMJ. 321:2000;1183-1187
13. Garcia Rodriguez L.A., Hernandez-Diaz S. Risk of uncomplicated peptic ulcer among users of aspirin and non-aspirin NSAIDs. Am J Epidemiol. 159:2004;23-31
14. Fries J.F., Bruce B. Rates of serious gastrointestinal events from low dose use of acetylsalicylic acid, acetaminophen, and ibuprofen in patients with osteoarthritis and rheumatoid arthritis. J Rheumatol. 30:2003;2226-2233
15. Weil J., Colin-Jones D., Langman M., Lawson D., Logan R., Murphy M., Rawlins M., Vessey M., Wainwright P. Prophylactic aspirin and risk of peptic ulcer bleeding. BMJ. 31:1995;827-830
16. Cryer B., Feldman M. Effects of very low dose daily, long-term aspirin therapy on gastric, duodenal, and rectal prostaglandin levels and on mucosa injury in healthy humans. Gastroenterology. 117:1999;17-25
17. Feldman M., Cryer B., Mallat D., Go M.F. Role of Helicobacter pylori infection in gastroduodenal injury and gastric prostaglandin synthesis during long term/low dose aspirin therapy. Am J Gastroenterol. 96:2001;1751-1757
18. Chan F.K.L., Chung S., Suen B.y., Lee Y.T., Leugh W.K., Leung V.K.S., Wu J.C.Y., Lau J.Y.M., Hui Y., Lai M.S., Chan H.L.Y., Sung J.Y. Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N Engl J Med. 344:2001;967-973
19. Kaufman D.W., Kelly J.P., Wiholm B.E., Laszlo A., Sheehan J.E., Koff R.S., Shapiro S. The risk of acute major upper gastrointestinal bleeding among users of aspirin and ibuprofen at various levels of alcohol consumption. Am J Gastroenterol. 94:1999;3139-3196
20. Fioruccci S., Menezes, Menez de Lima O. Jr, Mencarelli A., Palzetti B., Distrutti E., McKnight W., DiCay M., Ma L., Romano M., Morelli A., Wallace J.L. Cyclooxygenase-2 derived lipoxin A4 increases gastric resistance to aspirin-induced damage. Gastroenterology. 123:2002;1598-1606
21. Fiorucci S., Santucci L., Wallace J.L., Sardina M., Romano M., del Soldato P. Interaction of a selective cyclooxygenase-2 inhbibitor with aspirin and NO releasing aspirin in the human gastric mucosa. Proc Natl Acad Sci. 100:2003;10937-10941
22. McMahon B., Godson C. Lipoxins endogenous regulators of inflammation. Am J Physiol Renal Physiol. 286:2004;F189-F201
23. Silverstein F.E., Faich G., Goldstein J.L., Simon L.S., Pincus T., Whelton A., Makuch R., Eisen G., Agrawal N.M., Stenson W.F., Burr A.M., Zhao W.W., Kent J.D., Lefkowith J.B., Verburg K.M., Geis G.S. Gastrointestinal toxicity with celecoxib vs. nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib long-term arthritis safety study. JAMA. 284:2000;1247-1255
24. Darling R.L., Romero J.J., Dial E.J., Akunda J.K., Langenbach R., Lichtenberger L.M. Effects of aspirin on gastric mucosal integrity, hydrophobicity and prostaglandin metabolism in cyclooxygenase knockout mice. Gastroenterology. 127:2004;94-104
25. Lichtenberger L.M., Wang Z.-M., Romero J.J., Ulloa C., Perez J.C., Giraud M.-N., Barreto J.C. NSAIDs associate with zwitterionic phospholipids insight into the mechanism and reversal of NSAID-induced gastrointestinal injury. Nature Med. 1:1995;154-158
26. Anand B.S., Romero J.J., Sanduja S.K., Lichtenberger L.M. Phospholipid association reduces the gastric toxicity of aspirin in human subjects. Am J Gastroenterol. 94:1999;1818-1822
27. Lichtenberger L.M., Romero J.J., DeRuijter W.M.J., Behbod F., Darling R., Ashraf A.Q., Sanduja S.K. Phosphatidylcholine association increases the anti-inflammatory and analgesic activity of ibuprofen in acute and chronic rodent models of joint inflammation. J Pharmacol Exp Ther. 298:2001;279-287
28. Wallace J.L., Zamuner S.R., McKnight W., Dicay M., Mencarelli A., del Soldato P., Fiorucci S. Aspirin, but not NO-releasing aspirin (NCX-4016), interacts with selective COX-2 inhibitors to aggravate gastric damage. Am J Physiol Gastrointest Liver Physiol. 286:2004;G76-81
29. Capone M.L., Tacconelli S., Sciulli M.G., Grana M., Ricciotti E., Minuz P., Di Gregorio P., Merciaro G., Patrono C., Patrignani P. Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects. Circulation. 190:2004;1468-1471